Calamos Advisors
AGN

Calamos Advisors’s Allergan plc AGN Stock Holding History

Calamos Advisors’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-36,200
Closed -$6.04M – 735
2018
Q2 		$6.04M Buy
+36,200
New +$5.81M 0.04% 398
2018
Q1 		– Sell
-90,000
Closed -$14.7M – 638
2017
Q4 		$14.7M Hold
90,000
– – 0.08% 246
2017
Q3 		$21K Hold
90,000
– – ﹤0.01% 613
2017
Q2 		$21.9M Buy
90,000
+89,100
+9,900% +$20.9M 0.16% 181
2017
Q1 		$455K Buy
+900
New +$210K ﹤0.01% 565

Other funds holding AGN

AJ
Ashburton (Jersey) St Helier, Jersey $227M AUM
C
Cerebellum San Francisco, California $21.5M AUM
B
Barings Charlotte, North Carolina $5.64B AUM 18.33% 1-Year Est. Return
JJ
JDC-JSC New York $20.8M AUM 30.94% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

Calamos Advisors's AGN Position: Q2 2020 in Review

Calamos Advisors sold out of Allergan plc (AGN) in Q2 2020, closing a stake of 378,418 shares — an estimated $67M sold.

Calamos Advisors first reported a position in AGN in Q4 2013 and held it in 26 quarters. The position peaked at $128M in Q1 2018. 7 funds tracked by Wall St. Rank hold AGN as of Q2 2020.

  • Calamos Advisors reported no remaining Allergan plc position as of Q2 2020 after selling out during the quarter.
  • Calamos Advisors sold 378,418 Allergan plc shares in Q2 2020, an estimated $67M.
  • Calamos Advisors first reported a position in Allergan plc in Q4 2013 and held it in 26 quarters.
  • Calamos Advisors's Allergan plc position peaked at $128M in Q1 2018.
  • 7 funds tracked by Wall St. Rank held Allergan plc as of Q2 2020.

Based on Calamos Advisors's 13F filing for Q2 2020, filed 27 Jul 2020.